LODOCO is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.
Do not take LODOCO if you:
When added to standard therapy in adults with ASCVD.
Licensed telehealth providers can assess your cardiovascular risk and discuss whether treatment is appropriate.
For eligible commercially insured patients. See pricing details.
* Nidorf SM, Fiolet ATL, et al. N Engl J Med. 2020;383(19):1838–47.
When added to standard therapy in adults with ASCVD.
Licensed telehealth providers can assess your cardiovascular risk and discuss whether treatment is
appropriate.
¹ Nidorf SM, Fiolet ATL, et al. N Engl J Med. 2020;383(19):1838–47.
LODOCO is FDA-approved to reduces the risk of heart attack, stroke, and cardiovascular death in
adults with existing cardiovascular disease or multiple risk factors.
It’s taken once daily and is specifically formulated for long-term cardiovascular care.
You may be a candidate for LODOCO if you:
You are now leaving a branded site and visiting an independent disease awareness resource.
Schedule a telehealth appointment here
Request your prescription be sent to BlinkRx or Marley
Get LODOCO shipped to your home with free delivery
Pay as little as $30 for a 90-day supply
Get LODOCO for $99/month via BlinkRx or Marley — shipping included
You may qualify for our Patient Assistance Program
LODOCO is supported by cardiovascular outcomes data and indicated for adults with ASCVD or multiple risk factors.
Want to learn more about cardiovascular inflammation and residual risk?
Want to learn more about cardiovascular inflammation and residual risk?
Visit CVDInflammation.com
You are now leaving a branded website and entering an unbranded educational resource.
